DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20220910
Published: 2022-03-25

A study of efficacy of ormeloxifene in abnormal uterine bleeding of ovulatory disorders

Nandhini G. M., Hiremath P. B., Shameera Banu A.

Abstract


Background: Abnormal uterine bleeding (AUB) of ovulatory disorders is defined as the state of abnormal bleeding from the genital tract without any clinically detectable organic, systemic and iatrogenic cause. AUB is one of the common gynaecological issues among the patients visiting the hospital as it could affect at least 1/3rd of women in the child bearing age. Ormeloxifene, a nonsteroidal, nonhormonal and selective estrogen receptor modulator is a highly safe drug in treating acute and abnormal menstrual bleeding.  

Methods: The 40 cases of heavy menstrual bleeding (HMB) with ovulatory disorder in the range of 40-52 years of age were treated with 60 mg ormeloxifene twice a week for first 12 weeks and once a week for next 12 weeks.  The patients were evaluated for haemoglobin, pictorial blood loss assessment chart (PBAC) score and endometrial thickness before and after treatment.

Results: A significant decrease in endometrial thickness and PBAC score was observed. Also, the level of haemoglobin is found to increase significantly from 8.4±0.8 to 9.9±0.7. In this study, following 6 months of treatment with ormeloxifene, 90% of cases had marked improvement in their symptoms, while 10% of the patients required surgical management i.e., hysterectomy. Amenorrhea was observed in 7.5% of total cases and hypomenorrhea in 5% cases.

Conclusions: Based on these results we could conclude that ormeloxifene could be the drug of choice in patients with AUB as it is very safe with manageable side effects. This simple drug-based therapy has facilitated compliance, tolerability and noticeable reduction of symptoms resulting in satisfaction towards the treatment.


Keywords


Ormeloxifene, HMB, AUB, Dysfunctional uterine bleeding, PBAC, Selective estrogen receptor modulator

Full Text:

PDF

References


Hiralal K. DC Dutta’s Textbook of Gynecology. 7th ed. India: Jaypee; 2016.

Singh HO, Singh A, Dhole TN, Nain S. Effect of ormeloxifene for management of dysfunctional uterine bleeding. Biochem Physiol. 2015;4:174.

Dhananjay BS, Sunil Kumar N. The Role of Sevista in the Management of Dysfunctional Uterine Bleeding. J Clin Diagnostic Res. 2013;7(1):132134.

Tapasi P, Kabita C, Satyabhama M, Jagadish H. Ormeloxifene-Looking beyond contraception. J Midlife Health. 2017;8(1);17-20.

Ravibabu K, Jayasree P, Ganapathiswamy C. A Study of Efficacy of Ormeloxifene in the Pharmacological Management of Dysfunctional Uterine Bleeding. J Clin Diagnostic Res. 2013;7(11):2534-6.

Tajinder K, Rakesh CC, Amrita C. Study of Efficacy and Safety of Ormeloxifene in Management of Abnormal Uterine Bleeding. Int J Contemporary Med Res. 2018;5(1):B1-4.

Vijaya S, Mahalakshmi M. Efficacy of ormeloxifene in the medical management of abnormal uterine bleeding. Stanley Med J. 2017;4(4):37-40.

Agarwal N, Singh S, Singh S, Agarwal M, Manocha P. Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding. Int J Reprod Contrac Obstetr Gynecol. 2013;2(2):194-9.

Masand D, Gupta S, Patel J. To observe effect of ormeloxifene in medical management of dysfunctional uterine bleeding. J Evolution Med Dental Sci. 2015;4(4):587-98.

Anjum S, Agrawal A, Kulshreshtha S, Sharma R. To study the effect of ormeloxifene in management of perimenopausal dysfunctional uterine bleeding. J Evolution Med Dental Sci. 2015;4(73):12639-45.

Suhasini K, Lakshmi G, Padma Y, Sabitha C. Reduced dose of ormeloxifene in dysfuncitonal uterine bleeding-safety and effectiveness. J Evolution Med Dental Sci. 2016;5(14):664-70.

Kumari A, Prakash R. The role of ormeloxifene in the management of dysfunctional uterine bleeding: A prospective clinical study. Int J Contemp Med Res. 2018;5:6-11.

Hymavathi K, Gottipati MD, Sudha V. Ormeloxifene versus Tranexamic acid in dysfunctional uterine bleeding comparative evaluation. Int J Reprod Contrac Obstetr Gynecol. 2018;7(2):566-71.

Agarwal P, Shinde U, Shinde S, Aher G. Efficacy of Ormeloxifene vs Norethisterone in the Management of Perimenopausal DUB. VIMS Health Sci J. 2019;6(2):30-3.

Arunadevi V, Minnalkodi SN. Ormeloxifene versus oral contraceptive pills in the management of DUB. Int J Clin Obstetr Gynecol. 2020;4(2):81-5.

Varwatte PB, Fonseca M. Study of the efficacy of ormeloxifene in abnormal uterine bleeding. Int J Reprod Contrac Obstetr Gynecol. 2020;9(12):4941-6.

Biswas SC, Saha SK, Bag TS. Ormeloxifene a selective estrogen receptor modulator, for treatment of dysfunctional uterine menorrhagia. J Obstet Gynaecol Ind. 2004;54(1):56-9.

Manisha N, Ranjan V, Srivastava S, Sharma. Centchroman induces the G0/G1 arrest and the caspase-dependent apoptosis which involves the mitochondrial membrane depolarization in the MCF-7 and the MDA MB-231 human breast cancer cells. Life Sci. 2008;82:577-90.